Skip to Main Content

Author Details

Jianjun Zhang
The University of Texas MD Anderson Cancer Center
2012
158
43
PMIDPaper TitleJournal TitlePublished Year
37717855Genetic Intratumor Heterogeneity Remodels the Immune Microenvironment and Induces Immune Evasion in Brain Metastasis of Lung Cancer.J Thorac Oncol2024
36239535Bayesian hierarchical quantile regression with application to characterizing the immune architecture of lung cancer.Biometrics2023
38019649TimiGP: An R package to depict the tumor microenvironment from bulk transcriptomics.STAR Protoc2023
37961165A novel Bayesian model for assessing intratumor heterogeneity of tumor infiltrating leukocytes with multi-region gene expression sequencing.bioRxiv2023
37592034Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer.Nat Rev Clin Oncol2023
37655662Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer.J Clin Invest2023
37586362Archival single-cell genomics reveals persistent subclones during DCIS progression.Cell2023
37478883Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.Lancet2023
37694148Immune-active tumor-adjacent tissues are associated with favorable prognosis in stage I lung squamous cell carcinoma.iScience2023
37835518Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis.Cancers (Basel)2023
37733794ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.Clin Cancer Res2023
37876834Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues.Oncoimmunology2023
37678674Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma.Mod Pathol2023
37675380Case Report: Immune checkpoint inhibitor-induced multiorgan vasculitis successfully treated with rituximab.Front Nephrol2023
38090518The opportunities and challenges of perioperative therapy of localized non-small cell lung cancer-thoughts from the KEYNOTE-671 trial.Transl Lung Cancer Res2023
37637041Radiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operations.Front Oncol2023
37156009Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience.Oncologist2023
36948240Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer.Cancer Lett2023
37467716TimiGP: Inferring cell-cell interactions and prognostic associations in the tumor immune microenvironment through gene pairs.Cell Rep Med2023
37406091EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer.Proc Natl Acad Sci U S A2023
37337757A novel statistical method for decontaminating T-cell receptor sequencing data.Brief Bioinform2023
37268451Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.Lancet Digit Health2023
37068173Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.Cancer Discov2023
37432985Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.Clin Cancer Res2023
37296880New Actions on Actionable Mutations in Lung Cancers.Cancers (Basel)2023
36998720EasyCellType: marker-based cell-type annotation by automatically querying multiple databases.Bioinform Adv2023
36788067Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer.Mod Pathol2023
36716413Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals <i>EGFR</i> Mutations to Be Associated With Longer Overall Survival.JCO Precis Oncol2023
36765572MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities.Cancers (Basel)2023
36703611Analysis of genomic and immune intratumor heterogeneity in linitis plastica via multiregional exome and T-cell receptor sequencing.Mol Oncol2023
36597662Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort.Cancer2023
36413126T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy.Clin Cancer Res2023
36928818Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.Nat Med2023
36755027Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer.Nat Commun2023
34740862Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.J Thorac Oncol2022
35546239Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma.J Exp Clin Cancer Res2022
35440668Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.Br J Cancer2022
35379845MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.Nat Commun2022
35471938Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer.JCI Insight2022
35697807Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression.Nat Biotechnol2022
35666500Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab.JAMA Netw Open2022
35820397Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.Cancer Cell2022
35421082Abnormal global alternative RNA splicing in COVID-19 patients.PLoS Genet2022
36636418Neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?Transl Lung Cancer Res2022
35973335Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment.Lung Cancer2022
36303017Netie: inferring the evolution of neoantigen-T cell interactions in tumors.Nat Methods2022
36195615Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer.Signal Transduct Target Ther2022
35884533Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma.Cancers (Basel)2022
36282981Artificial Intelligence in Digital Pathology to Advance Cancer Immunotherapy.21 Century Pathol2022
35944232Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set.JCO Clin Cancer Inform2022
  • 1 - 50 of 158

Recommended Authors

Daniel Kazdal
Institut fur Pathologie, Universitatsklinikum Heidelberg
Career Start Year 2016
Number of shared co-authors 2
Daniel W Kelly
Memorial Sloan Kettering Cancer Center
Career Start Year 2016
Number of shared co-authors 3
David C Qian
Winship Cancer Institute of Emory University
Career Start Year 2015
Number of shared co-authors 1
Philipp Jurmeister
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Career Start Year 2015
Number of shared co-authors 1
David A Moore
University College London Cancer Institute
Career Start Year 2012
Number of shared co-authors 7
Jyoti Malhotra
Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School
Career Start Year 2012
Number of shared co-authors 3
Arshi Arora
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 3
Siddhartha Devarakonda
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2011
Number of shared co-authors 5
Caroline E McCoach
UCSF Helen Diller Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 4
Vibha Raghavan
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2009
Number of shared co-authors 1
Eliezer M Van Allen
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 22
Ashiq Masood
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Career Start Year 2008
Number of shared co-authors 1
Martina Kirchner
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2007
Number of shared co-authors 2
Yang Xie
Quantitative Biomedical Research Center
Career Start Year 2007
Number of shared co-authors 10
Li Liu
Central South University
Career Start Year 2006
Number of shared co-authors 0
Iacopo Petrini
University of Pisa
Career Start Year 2006
Number of shared co-authors 1
Fengshen Kuo
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 2
Matthew A Gubens
University of California san francisco
Career Start Year 2003
Number of shared co-authors 7
Volker Endris
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2001
Number of shared co-authors 3
Benjamin Solomon
Peter MacCallum Cancer Centre
Career Start Year 2000
Number of shared co-authors 8
Daniel Morgensztern
Washington University School of Medicine
Career Start Year 2000
Number of shared co-authors 6
David Neil Hayes
Center for Cancer Research, University of Tennessee Health Science Center
Career Start Year 1999
Number of shared co-authors 33
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 18
Patrick Micke
Uppsala University
Career Start Year 1997
Number of shared co-authors 0
Prudence A Russell
St Vincent's Hospital
Career Start Year 1997
Number of shared co-authors 3
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 22
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 27
Michael Allg??uer
Institute of Pathology, Heidelberg University Hospital
Career Start Year 1991
Number of shared co-authors 2
Ramaswamy Govindan
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 1981
Number of shared co-authors 24
Ming-Sound Tsao
University Health Network, University of Toronto
Career Start Year 1972
Number of shared co-authors 24

Collaborators

Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Co-authored papers 46
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Co-authored papers 27
Lixia Diao
The University of Texas MD Anderson Cancer Center
Co-authored papers 14
Curtis Gumbs
The University of Texas MD Anderson Cancer Center
Co-authored papers 13
Paul Scheet
University of Texas M.D. Anderson Cancer Center
Co-authored papers 11
Daniel R Gomez
Memorial Sloan Kettering Cancer Center
Co-authored papers 11
Xingzhi Song
The University of Texas MD Anderson Cancer Center
Co-authored papers 10
Steven H Lin
University of Texas MD Anderson Cancer Center
Co-authored papers 8
Jennifer A Wargo
Co-authored papers 7
Linghua Wang
The University of Texas M. D. Anderson
Co-authored papers 6
Daniel J McGrail
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Co-authored papers 6
Chao Cheng
Baylor College of Medicine
Co-authored papers 5
Charles Lu
Co-authored papers 5
John D Minna
University of Texas Southwestern Medical Center at Dallas
Co-authored papers 4
Roy S Herbst
Yale School of Medicine
Co-authored papers 4
Steven M Dubinett
David Geffen School of Medicine at university of california los angeles
Co-authored papers 4
Avrum Spira
Boston University School of Medicine
Co-authored papers 4
Mei Jiang
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Jerry Fowler
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Michael A Davies
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Vincent A Miller
Injury Prevention Research Center, University of North Carolina
Co-authored papers 3
Scott Kopetz
University of Texas MD Anderson Cancer Center
Co-authored papers 3
Hira Rizvi
Druckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Mark J Routbort
University of Texas MD Anderson Cancer Center
Co-authored papers 3
James K Hicks
H. Lee Moffitt Cancer Center and Research Institute
Co-authored papers 3
Sherise D Ferguson
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Sahil Seth
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Wenyi Wang
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
David A Palma
University of Western Ontario
Co-authored papers 2
Adel K El-Naggar
MD Anderson Cancer Center
Co-authored papers 2
Release 1.2